Business
Update re Positive VAL201 & Biomarker Unit Studies
Update re Positive VAL201 & Biomarker Unit Studies.
About this update from Valirx Plc
[{"type":"text","content":"\n \nRNS Number : 1249U ValiRx PLC 28 November 2013 \n\n \n \n28 November 2013\n \nValiRx Plc\n \n(\"ValiRx\" or the \"Company\")\n \nUpdate re Positive VAL201 & Biomarker Unit Studies\n \nValiRx Plc (AIM: VAL), a life science company with a focus on cancer therapeutics for personalised medicine, is pleased to announce that it has received encouraging and positive reports from the Group's laboratory and biomarker unit, ValiFinn, in Finland, on the integral biomarker work associated with VAL201's First in man trial, ValiRx's leading anti-cancer therapeutic compound, which currently is in the clinical development phase for prostate and other hormone induced cancer indications.\nTwo full reports have been provided on VAL201, from Finnish Government supported studies conducted at ValiFinn.\nFrom these reports and in confirmation of previous proof of concept studies, VAL201 demonstrated a reducing effect on both hormone dependent and independent prostate cancer cells. The study investigated the diagnostic capability and the efficacy of the biomarkers for assessing the proliferation of cancer cells and measured levels of PSA, the usual prostate cancer diagnostic marker*. \nSignificantly, the cancer cell proliferation and tumour reducing effect can be measured with both markers and by the direct measurement of reduced cancer cell proliferation in a drug dose dependent manner. This information means that a more comprehensive use of the marker diagnostics will be made in the therapeutic clinical assessment of VAL201. The assays for these biomarkers are proven for use in the clinical trial and they will be used as part of the assessment of the trial outcome.\nA second encouraging study delivered preliminary positive results in non-hormonal breast cancer models, using cell viability and cell growth markers. In this study, VAL201 was shown to decrease the proliferation or spread of cancer cells, as measured by the markers.\n \n \nDr Satu Vainikka, CEO of ValiRx, commented: \n\"ValiRx's ability to use biomarkers to measure the reducing effect VAL201 has on prostate cancer models, is very encouraging and we are excited to see that by using different biomarkers, we have been able to measure VAL201's impact on reducing both the proliferation and spread of the prostate canc...